An expert discusses how the positive efficacy findings from the phase 3 RESPONSE trial, showing high rates of hematocrit control and spleen response with ruxolitinib vs standard therapy in hydroxyurea-resistant/intolerant polycythemia vera (PV), have enhanced the treatment approach for patients with inadequate response to hydroxyurea.
An expert discusses how advances in JAK V617F monitoring have improved the assessment of disease status and guided treatment decisions and how risk assessment tools have transformed the ability to optimize treatment selection in patients with myeloproliferative neoplasms (MPNs).
Panelists discuss how chimeric antigen receptor (CAR) T-cell therapy could potentially be moved to earlier lines of treatment in relapsed/refractory multiple myeloma based on emerging trial data, improving outcomes through earlier intervention before patients develop treatment resistance.
A panelist discusses how the integration of immunotherapy into recurrent/metastatic (R/M) nasopharyngeal carcinoma (NPC) treatment requires careful patient monitoring for immune-related adverse events, strategic sequencing with other modalities, consideration of biomarker-guided approaches, and awareness of emerging combination strategies that may further improve outcomes, while ongoing research into novel immunotherapeutic agents, maintenance strategies, and treatment de-escalation protocols aims to optimize efficacy while minimizing toxicity in the evolving landscape of NPC management.
A panelist discusses how immunotherapy combined with chemotherapy has revolutionized recurrent/metastatic (R/M) nasopharyngeal carcinoma (NPC) treatment through improved survival outcomes demonstrated in landmark trials such as JUPITER-02 with toripalimab and KEYNOTE-590 with pembrolizumab, emphasizing that although most patients benefit regardless of PD-L1 status or Epstein-Barr virus positivity, clinicians must carefully consider patient-specific factors, such as performance status and comorbidities, alongside the management of unique immune-related adverse events through early recognition, established treatment algorithms, and multidisciplinary collaboration to optimize outcomes in this evolving treatment landscape.
A panelist discusses how treatment strategies for recurrent nasopharyngeal carcinoma (NPC) have evolved, with the updated NCCN guidelines now recommending toripalimab plus gemcitabine/cisplatin as category 1 first-line therapy for recurrent/metastatic (R/M) disease based on the JUPITER-02 trial results showing significantly improved 4-year overall survival (OS) rates of 48% vs 27.7% with chemotherapy alone, while emphasizing that treatment decisions should consider patient-specific factors, such as Epstein-Barr virus status, prior treatments, and comorbidities, alongside nonpatient factors, including drug accessibility, need for rapid response, and capacity to manage immune-related adverse events.
A panelist discusses how a 48-year-old man with recurrent nasopharyngeal carcinoma (NPC) presents with nasal congestion, epistaxis, neck swelling, and unilateral hearing issues, highlighting the importance of recognizing these symptoms in patients with a family history of NPC.
A panelist discusses how nasopharyngeal carcinoma (NPC) differs from other head and neck malignancies through its distinct geographical distribution, Epstein-Barr virus association, unique genetic profile, and characteristic clinical presentation, including early lymph node involvement.
Panelists discuss how RATIONALE-305 represents a significant advancement in first-line treatment for advanced gastric cancer with tislelizumab demonstrating meaningful survival benefits while maintaining a tolerable safety profile that could potentially reshape standard clinical practice.
Panelists discuss how the optimal sequencing between available therapies for advanced gastric cancer remains challenging but should be guided by patient-specific factors, prior treatment response, and molecular characteristics of the tumor.
Panelists discuss how the RATIONALE-305 trial revealed a manageable adverse event profile for tislelizumab plus chemotherapy despite increased rates of neutropenia and anemia compared to placebo plus chemotherapy in advanced gastric cancer patients.
Panelists discuss how RATIONALE-305 trial data shows promising updated overall survival benefits for patients receiving tislelizumab plus chemotherapy compared to placebo plus chemotherapy in advanced gastric or gastroesophageal junction adenocarcinoma.
An expert discusses alternative treatment options for a symptomatic patient with metastatic castration-resistant prostate cancer (mCRPC) and highlights the caveats around the data from the Phase 3 ALSYMPCA study of radium-223, including its conduct in an era prior to the introduction of abiraterone (ABI) and enzalutamide (ENZA).
A panelist discusses how emerging research in RCC treatment encompasses several promising investigational approaches that could potentially reshape the therapeutic landscape, from novel drug combinations to innovative treatment strategies that may address current gaps in care.
An expert discusses how recent analyses from the REFLECT trial in unresectable hepatocellular carcinoma (uHCC) demonstrate that both achieving objective response and greater depth of response correlate with improved survival outcomes. The depth of response serves as a potentially valuable early biomarker for prognosis and treatment decisions, with deeper responses associated with better overall survival among responders.
An expert discusses how treatment selection for first-line (1L) tyrosine kinase inhibitor (TKI) therapy in advanced hepatocellular carcinoma (HCC) requires careful evaluation of multiple factors, including liver function (Child-Pugh status), ECOG performance status, tumor burden, and presence of macrovascular invasion or extrahepatic spread. In reviewing individual cases, clinicians assess liver enzyme levels, α-fetoprotein values, radiographic findings, and comorbidities.
A panelist discusses how managing adverse events associated with TKIs and belzutifan requires a proactive approach encompassing prevention strategies, regular monitoring, dose modifications when needed (particularly for combination regimens), and evidence-based mitigation techniques, while considering the distinct toxicity profiles of each agent and the impact of dose adjustments on treatment efficacy.
A panelist discusses how community practitioners should monitor for immune-related adverse events when using toripalimab for recurrent/metastatic (R/M) nasopharyngeal carcinoma (NPC), establish clear patient communication about toxicities, coordinate multidisciplinary care, consider EBV monitoring, and ensure appropriate patient selection to optimize outcomes.
A panelist discusses A panelist discusses how the integration of immunotherapy with chemotherapy as first-line treatment for recurrent/metastatic (R/M) nasopharyngeal carcinoma (NPC) is transforming the treatment landscape, with data from trials such as JUPITER-02 and DIPPER demonstrating improved progression-free and overall survival outcomes, while patient selection factors including performance status, comorbidities, PD-L1 expression, and EBV status remain critical considerations for optimizing therapeutic benefit in both the metastatic setting and potentially in neoadjuvant/adjuvant approaches.
A panelist discusses how low baseline EBV levels still showed benefit from toripalimab in JUPITER-02, though EBV status influences treatment decisions and alternative markers are needed for EBV-negative cases.
A panelist discusses how toripalimab has emerged as the preferred treatment regimen for metastatic nasopharyngeal carcinoma (NPC), according to NCCN guidelines, based on improved survival outcomes in clinical trials compared with traditional chemotherapy approaches alone, though individual patient factors including performance status, prior treatments, and specific tumor characteristics must be carefully considered when personalizing the treatment strategy.
A panelist discusses how the unclear request format creates ambiguity about which case is being referenced, making it difficult to provide specific details that stand out without additional context.
Panelists discuss next-generation ROS1 inhibition, highlighting emerging therapies, their mechanisms of action, and potential benefits for patients with ROS1-positive metastatic non–small cell lung cancer.
Panelists discuss the presentation and management of a case involving metastatic non–-small cell lung cancer (NSCLC) with a ROS1 alteration, focusing on treatment approaches and clinical considerations
Panelists discuss how combining systemic therapy with locoregional treatments like transarterial chemoembolization (TACE) aims to enhance therapeutic efficacy by addressing its limitations, such as incomplete tumor necrosis and hypoxia-induced progression. Tyrosine kinase inhibitors (TKIs) like lenvatinib and immune checkpoint inhibitors (ICIs) counteract TACE-induced resistance by inhibiting angiogenesis and boosting immune response, improving overall tumor control.
An expert discusses using sequence therapies based on disease progression, patient factors, and resistance mechanisms. After a first-line tyrosine kinase inhibitor plus immune checkpoint inhibitor (TKI + ICI) regimen, preferred subsequent-line options include alternative TKIs, chemotherapy, or combination strategies, tailored to patient response and tolerability.
Panelists discuss how systemic therapy plays a crucial role in embolization-eligible hepatocellular carcinoma (HCC), particularly for patients with progressive or extensive disease. In locally advanced cases, systemic therapies, including immunotherapy combinations and tyrosine kinase inhibitors (TKIs), are first-line options. Patients typically transition from transarterial chemoembolization (TACE) to systemic therapy upon progression, high tumor burden, or liver function decline.
An expert discusses how third line (3L) systemic therapy for metastatic renal cell carcinoma (mRCC) is guided by prior treatments, patient comorbidities, and drug-specific profiles. Options include tyrosine kinase inhibitors (TKIs; eg, tivozanib, cabozantinib), mTOR inhibitors (eg, everolimus), and immune-oncology– based approaches. Efficacy, tolerability (grade 3/4 adverse events [AEs]), and pharmacokinetic (PK) differences drive selection. Dose modifications, such as for tivozanib and lenvatinib/everolimus, balance efficacy and safety. Selection prioritizes sequencing strategy, with evidence (eg, Pal 2022) supporting reduced-dose efficacy.
The panelist discusses how for patients initially eligible for embolization, systemic therapy may be combined with transarterial chemoembolization (TACE) upfront for high-risk disease (ie, large tumor burden, elevated AFP) or reserved for progression after regional therapy in lower-risk cases. Treatment decisions should be individualized based on tumor characteristics, liver function, and patient preferences.
A panelist discusses how patient-reported outcomes have transformed their ability to deliver more personalized care approaches for patients with polycythemia vera (PV) by providing critical insights into symptom burden, quality-of-life impacts, and treatment effectiveness that might otherwise go unrecognized through standard clinical assessments alone.